Sobi Launches Orfadin® (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1)

- Program to provide peer-to-peer education within the HT-1 community -

Read more

New data show extended prophylactic dosing with Alprolix® provides safe and effective protection in people with severe haemophilia B

Post-hoc longitudinal analysis from B-LONG and B-YOND studies shows patients who progressed to individualised prophylactic dosing intervals of 14 days...

Read more

Study shows weekly prophylactic treatment with Elocta® resulted in bleed protection and target joint resolution in people with haemophilia A

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVV) today announce the results of a new, post-hoc, longitudinal...

Read more

Sobi Receives Approval from Health Canada for Orfadin® (nitisinone) Oral Suspension for the Treatment of HT-1

- First liquid formulation nitisinone product approved in Canada; developed by Sobi to meet the needs of small children and patients who have difficulty swallowing capsules -

 

Read more

Sobi receives approval from Health Canada for Orfadin® oral suspension for the treatment of HT-1

Swedish Orphan Biovitrum AB (publ) (Sobi™) has received approval from Health Canada for an oral suspension formulation of Orfadin® (nitisinone)....

Read more

First patient randomised in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still’s disease

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been randomised in the phase 3 study anaSTILLs, to evaluate efficacy...

Read more

Interim data published in Haemophilia show improvements in long-term joint health for haemophilia A patients after prophylactic treatment with Elocta®

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today announces the publication of interim results from a...

Read more

Interim data published in Haemophilia show improvements in long-term joint health for haemophilia A patients after prophylactic treatment with Elocta®

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today announces the publication of interim results from a...

Read more

The first patient enrolled in the ReITIrate study evaluating immune tolerance induction with Elocta®

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces today that the first patient has been enrolled in the open-label, multicentre ReITIrate study...

Read more

Alprolix® approved in the Kingdom of Saudi Arabia for the treatment of haemophilia B

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved...

Read more

Archive